Literature DB >> 23205088

Antitumor effect and immune response induced by local hyperthermia in B16 murine melanoma: Effect of thermal dose.

Dan Ye Li1, Yang Ping Tang, Ling Yun Zhao, Chuan Ying Geng, Jin Tian Tang.   

Abstract

This study aimed at investigating the antitumor effect and immune response induced by local high-temperature hyperthermia at different thermal doses in B16 murine melanoma. The screened optimal thermal dose (50°C, 15 min) which was demonstrated to be the most effective in immune response activation was applied to the treatment of lung metastasis. The optimal thermal dose was determined by evaluating the tumor volume change, survival period of tumor-bearing mice, and immune indices including interleukin (IL)-2, interferon (IFN)-γ and TNF-α mRNA expression in the spleen of mice subjected to local hyperthermia at various thermal doses. The activation of the immune response was further investigated by rechallenging the cured mice 60 days after hyperthermia treatment. The screened optimal thermal dose combined with immunoadjuvant compound 48/80 was applied for melanoma lung metastasis. While local hyperthermia effectively inhibited B16 melanoma tumor growth and prolonged the survival period of tumor-bearing mice, the antitumor immunity was significantly enhanced and the effect was thermal dose-dependent. Higher temperatures (≥50°C) induced a significant effect even with a short treatment time (≤15 min). No tumor regrowth was observed for rechallenged B16 melanoma in mice following treatment with local hyperthermia at a higher temperature. Local hyperthermia by optimal thermal dose in combination with immunoadjuvant compound 48/80 is an effective approach for the treatment of B16 melanoma lung metastasis. This study indicated that the use of a local high-temperature hyperthermia protocol inhibits tumor growth and stimulates a favorable antitumor immune response against malignant melanoma. The results of these experiments may have clinical significance for the treatment of melanoma.

Entities:  

Year:  2012        PMID: 23205088      PMCID: PMC3506660          DOI: 10.3892/ol.2012.804

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

1.  Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.

Authors:  Marcello Pace; Riccardo Gattai; Erminia M Mascitelli; Luigi Millanta
Journal:  J Surg Oncol       Date:  2011-06-30       Impact factor: 3.454

2.  Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.

Authors:  Michelle Hong; Anne-Laure Puaux; Caleb Huang; Laure Loumagne; Charlene Tow; Charles Mackay; Masashi Kato; Armelle Prévost-Blondel; Marie-Françoise Avril; Alessandra Nardin; Jean-Pierre Abastado
Journal:  Cancer Res       Date:  2011-09-26       Impact factor: 12.701

Review 3.  Cutaneous melanoma.

Authors:  John F Thompson; Richard A Scolyer; Richard F Kefford
Journal:  Lancet       Date:  2005 Feb 19-25       Impact factor: 79.321

4.  Cell killing of melanoma B16 in vivo by hyperthermia and cytotoxins.

Authors:  R Stojkovic; M Radacic
Journal:  Int J Hyperthermia       Date:  2002 Jan-Feb       Impact factor: 3.914

5.  Inhibition of B16 murine melanoma metastasis and enhancement of immunity by fever-range whole body hyperthermia.

Authors:  Dewei Jia; Wei Rao; Chao Wang; Chao Jin; Suqiong Wang; Dongwei Chen; Minghui Zhang; Junwei Guo; Zhijie Chang; Jing Liu
Journal:  Int J Hyperthermia       Date:  2011       Impact factor: 3.914

Review 6.  Arrhenius relationships from the molecule and cell to the clinic.

Authors:  W C Dewey
Journal:  Int J Hyperthermia       Date:  1994 Jul-Aug       Impact factor: 3.914

7.  Mechanisms of histamine release by compound 48-80.

Authors:  A M Rothschild
Journal:  Br J Pharmacol       Date:  1970-01       Impact factor: 8.739

Review 8.  Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease.

Authors:  Parris Kidd
Journal:  Altern Med Rev       Date:  2003-08

9.  In situ tumor ablation creates an antigen source for the generation of antitumor immunity.

Authors:  Martijn H M G M den Brok; Roger P M Sutmuller; Robbert van der Voort; Erik J Bennink; Carl G Figdor; Theo J M Ruers; Gosse J Adema
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

10.  The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.

Authors:  Afton L McGowen; Laura P Hale; Christopher P Shelburne; Soman N Abraham; Herman F Staats
Journal:  Vaccine       Date:  2009-04-14       Impact factor: 3.641

View more
  6 in total

1.  Tumor vascular permeabilization using localized mild hyperthermia to improve macromolecule transport.

Authors:  Dickson K Kirui; Eugene J Koay; Xiaojing Guo; Vittorio Cristini; Haifa Shen; Mauro Ferrari
Journal:  Nanomedicine       Date:  2013-11-18       Impact factor: 5.307

2.  Stress-Induced, p53-Mediated Tumor Growth Inhibition of Melanoma by Modulated Electrohyperthermia in Mouse Models without Major Immunogenic Effects.

Authors:  Balázs Besztercei; Tamás Vancsik; Anett Benedek; Enikő Major; Mbuotidem J Thomas; Csaba A Schvarcz; Tibor Krenács; Zoltán Benyó; Andrea Balogh
Journal:  Int J Mol Sci       Date:  2019-08-17       Impact factor: 5.923

3.  In-vivo thermodynamic exploration of gas-based intraperitoneal hyperthermia.

Authors:  Agata Diakun; Tanja Khosrawipour; Agata Mikolajczyk-Martinez; Piotr Kuropka; Jakub Nicpoń; Zdzisław Kiełbowicz; Przemysław Prządka; Bartłomiej Liszka; Shiri Li; Hien Lau; Wojciech Kielan; Veria Khosrawipour
Journal:  Front Oncol       Date:  2022-08-29       Impact factor: 5.738

4.  Antitumor effects of high-temperature hyperthermia on a glioma rat model.

Authors:  Hidefumi Takagi; Kazuo Azuma; Takeshi Tsuka; Tomohiro Imagawa; Tomohiro Osaki; Yoshiharu Okamoto
Journal:  Oncol Lett       Date:  2014-02-04       Impact factor: 2.967

5.  HSPB1 deficiency sensitizes melanoma cells to hyperthermia induced cell death.

Authors:  He-Xiao Wang; Yang Yang; Hao Guo; Dian-Dong Hou; Song Zheng; Yu-Xiao Hong; Yun-Fei Cai; Wei Huo; Rui-Qun Qi; Li Zhang; Hong-Duo Chen; Xing-Hua Gao
Journal:  Oncotarget       Date:  2016-10-11

6.  Tre2-Bub2-Cdc16 Family Proteins Based Nomogram Serve as a Promising Prognosis Predicting Model for Melanoma.

Authors:  Ling Tang; Cong Peng; Su-Si Zhu; Zhe Zhou; Han Liu; Quan Cheng; Xiang Chen; Xiao-Ping Chen
Journal:  Front Oncol       Date:  2020-10-28       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.